Clinical evaluation has shown that DNA-PKcs is significantly increased in some types of tumors, such as prostate, lung, and hepatocellular tumors, and that DNA-PKcs dysregulation is closely related to the development of distant metastasis and reduced survival in prostatic cancer and melanoma [61]. This evidence concerns the gene PRKDC and prostate carcinoma.